News

Rocket Doctor Accepted Into Google’s AI First Accelerator and Unveils Cutting-Edge AI Patient Matching and Data Summarization Technologies

LAS VEGAS, NV / ACCESSWIRE / April 10, 2024 / Rocket Doctor, a trailblazer in virtual healthcare, proudly announces at…

2 years ago

Aptevo Therapeutics Provides Pipeline Update

Breast cancer patient who improved from a progressive disease diagnosis to an over nine-month sustained stable disease diagnosis has now…

2 years ago

PharmaCord Announces Appointment of Cindy Padgett to Chief Commercial Officer

JEFFERSONVILLE, IN / ACCESSWIRE / April 10, 2024 / PharmaCord LLC, a leading provider of patient support services for the…

2 years ago

Yunu Adds Pediatric Oncologist Dr. Scott Bradfield as Strategic Advisor

Collaboration aims to advance pediatric oncology trial precision with the latest imaging technology.CARY, NC / ACCESSWIRE / April 10, 2024…

2 years ago

Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study

The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammationTORONTO, April 10,…

2 years ago

Joint Statement Applauding Final Rule for Web Accessibility Under Title II of the ADA

WASHINGTON, April 10, 2024 (GLOBE NEWSWIRE) -- The American Council of the Blind (ACB), the American Foundation for the Blind…

2 years ago

New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

Lack of early symptom improvement is not predictive of final responder statusMALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics,…

2 years ago

BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will…

2 years ago

Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that…

2 years ago